Svetlana Nikic, Founder of Precision Oncology Consulting, shared Her post on LinkedIn, adding:
“If your diagnostic test is not reimbursed, it won’t be used at scale.
On October 29 (5pm CET), we will discuss what is blocking reimbursement and how we can accelerate it together with Lee-Anne Zinetti, Prithwish Pal, Tommi Lehtonen and Benjamin Gannon.
MAKE SURE TO REGISTER.”
Quoting Her post on LinkedIn:
“Only a minority of new oncology diagnostics achieve rapid, reimbursed uptake in Europe due to fragmented HTA processes and heterogeneous reimbursement pathways, that collectively slow market access.
This is why I’m incredibly excited to announce another live webinar titled ‘Healthcare Fragmentation in Europe: What It Means for Diagnostics and Precision Oncology,’ focusing on the complexities of European healthcare systems and reimbursement processes for diagnostic innovations.
Why is this important?
Well, the fragmented nature of European healthcare does not only create significant challenge for diagnostic companies seeking market access but it also delays the actual adoption of precision oncology by impacting the uptake of innovative therapies and, most critically, affect cancer patients’ quality of life and treatment outcomes.
I’m thrilled to have four exceptional individuals joining me to discuss these important topics, representing perspectives from early-stage cancer startups to well-established diagnostics and pharma providers. Their diverse experiences will provide comprehensive insights into navigating these challenges and hopefully we’ll even identify potential solutions.
Join me and these incredible four individuals on October 29th at 5pm CET.
Please REGISTER.”
Read more posts featuring Svetlana Nikic on OncoDaily.